about
The role and clinical implications of G6PI in experimental models of rheumatoid arthritisA functional variant of Fcgamma receptor IIIA is associated with rheumatoid arthritis in individuals who are positive for anti-glucose-6-phosphate isomerase antibodies.Induction of a B-cell-dependent chronic arthritis with glucose-6-phosphate isomeraseK/BxN Serum-Transfer Arthritis as a Model for Human Inflammatory ArthritisRoles of B cells in rheumatoid arthritisIdentification of a potent and orally active non-peptide C5a receptor antagonist.Clinical utility of the anti-CCP assay in patients with rheumatic diseases.Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory arthritis.The danger model approach to the pathogenesis of the rheumatic diseases.Ebola virus infection induces autoimmunity against dsDNA and HSP60Glycolysis and rheumatoid arthritis.DNA affects the composition of lipoplex protein corona: a proteomics approach.Altered peptide ligands inhibit arthritis induced by glucose-6-phosphate isomerase peptide.Diagnostic and prognostic values of anti glucose-6-phosphate isomerase antibodies in community-recruited patients with very early arthritis.Comparison of anti-mutated citrullinated vimentin, anti-cyclic citrullinated peptides, anti-glucose-6-phosphate isomerase and anti-keratin antibodies and rheumatoid factor in the diagnosis of rheumatoid arthritis in Chinese patients.Autoantibodies to Chemokines and Cytokines Participate in the Regulation of Cancer and Autoimmunity.A fork in the pathway to inflammation and arthritis
P2860
Q24799403-A3FFFC71-D3C8-4BC6-B948-60AAFA3112F2Q24812682-AC27B19D-C1DA-4AB0-BDE6-73D0F728525CQ24812914-E12A7AD7-3495-41BB-9A9E-A4434424A93AQ26745541-0BFA680D-4024-45F2-8E5A-EB7EF36D84FAQ33708839-AB45D885-FB97-451A-BCF0-F56AE6CCF293Q34154819-CED90B8A-4C93-48E6-82D8-DB35B67F4070Q35553110-A6B8A8A3-84A5-497F-B6AE-F91F09A35ED6Q35555539-7F647E77-EC9A-4D11-A6CA-732838AFAD25Q35564107-32B1E50A-FF11-42D9-A21E-472BFEC923E5Q37633570-6DB9C59C-D288-42EB-B3A1-C2E75523C36CQ37911558-22413AC9-B6DC-4A0E-B185-317BB4007486Q39729376-A0781D93-DA12-4CD2-BB32-4C7F7C75516FQ41201845-D68E5C7F-12C3-4CA9-B026-B92EDA7BB845Q45024317-A337319D-BBCA-44DC-8E3B-F52894086973Q50901659-D90A29CB-978D-4375-9F3F-D4ED5C8256A8Q55259964-62D65B13-6570-4642-8986-48A200C1CC67Q57232046-D23336AB-3851-4AAD-BB40-9542A48DAF8B
P2860
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Autoantibodies to GPI and creatine kinase in RA.
@en
Autoantibodies to GPI and creatine kinase in RA.
@nl
type
label
Autoantibodies to GPI and creatine kinase in RA.
@en
Autoantibodies to GPI and creatine kinase in RA.
@nl
prefLabel
Autoantibodies to GPI and creatine kinase in RA.
@en
Autoantibodies to GPI and creatine kinase in RA.
@nl
P2093
P356
P1433
P1476
Autoantibodies to GPI and creatine kinase in RA.
@en
P2093
David Schubert
Monika Schmidt
Peter R Jungblut
P304
411; author reply 412-3
P356
10.1038/NI0502-411A
P407
P577
2002-05-01T00:00:00Z